Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Las Palmas de Gran Canaria
Clinical trial register · Spain

Clinical Trials in Las Palmas de Gran Canaria, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca15 Merck Sharp & Dohme LLC13 AbbVie12 Incyte Corporation10 Sanofi8
Site location
Barcelona3238 Madrid3046 Valencia1215 Seville1054 Málaga746
All 453 locations
Target enrolment
to

Trials with a site in Las Palmas de Gran Canaria

203 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
Fernando Pessoa Canarias University
Not applicable
60
Las Palmas de Gran Canaria, Málaga
2027-03-31
Not yet open
Digital Prenatal Education to Reduce Fear of Childbirth in Term Pregnancy
NCT07743502Fear of Childbirth, Tocophobia, Pregnancy Related Anxiety
Sergio Mies Padilla
Not applicable
176
Las Palmas de Gran Canaria
2026-10-01
Recruiting
Carolina Ortiz Cortes
Observational
430
Santiago de Compostela, Donostia / San Sebastian, Úbeda, Las Palmas de Gran Canaria, Alcorcón, Boadilla del Monte, Leganés, Majadahonda
2026-09-17
Recruiting
Takeda
Phase 3
324
Badalona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Salamanca, Valencia
2026-09-10
Recruiting
Incyte Corporation
Phase 3
426
Alicante, Barcelona, Bilbao, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga
2026-09-08
Not yet open
Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer
NCT07717099Metastatic Hormone-Sensitive Prostate Cance
DrugsRa223·Darolutamide
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Phase 2
50
Barcelona, Las Palmas de Gran Canaria, Madrid, Oviedo, Santander, Santiago de Compostela, Valencia, Valladolid
2026-09
Recruiting
AstraZeneca
Phase 3
1,072
Barcelona, Castellon, Granada, Las Palmas de Gran Canaria, Madrid, Valencia, Vigo
2026-08-31
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc
DrugsEtoposide·Atezolizumab·Carboplatin
SystImmune Inc.
Phase 3
550
A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid
2026-08-04
Not yet open
Urinary Continence After Vaginal Surgery for Genital Prolapse in the Spanish Population.
NCT07628036Pelvic Organ Prolapse (POP), Pelvic Organ Prolapse Vaginal Surgery, Urinary Incontinence (UI)
Hospital Universitari Vall d'Hebron Research Institute
Observational
1,042
Barcelona, Santa Coloma de Gramenet, Murcia, Las Palmas de Gran Canaria
2026-08-01
Recruiting
IDP Discovery Pharma S.L.
Phase 1/2
60
Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Murcia, Pamplona, Santa Cruz de Tenerife, Valencia
2026-07-28
Recruiting
AstraZeneca
Phase 3
915
L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Santander, Seville
2026-07-16
Recruiting
AstraZeneca
Phase 3
150
Badajoz, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Huelva, Jaén, Las Palmas de Gran Canaria
2026-06-15
Recruiting
PETHEMA Foundation
Phase 2
50
Albacete, Alicante, Burgos, Cáceres, Córdoba, Las Palmas, Las Palmas de Gran Canaria, Lugo
2026-06-12
Recruiting
Eli Lilly and Company
Phase 3
252
A Coruña, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Seville, Valencia
2026-06-01
Recruiting
Incyte Corporation
Phase 1
218
Badalona, Las Palmas de Gran Canaria, Madrid
2026-05-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Badalona, Santander, Las Palmas de Gran Canaria, Madrid, Barcelona, Seville
2026-04-23
Recruiting
Incyte Corporation
Phase 3
588
Badalona, Barcelona, Las Palmas de Gran Canaria, Madrid, Palma de Mallorca, Santander, Seville, Valencia
2026-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
Las Palmas de Gran Canaria, Girona, Majadahonda, Barcelona, Madrid, Málaga, Seville
2026-03-18
Recruiting
Incyte Corporation
Phase 3
700
Badalona, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Palma de Mallorca, Pamplona, Pozuelo de Alarcón
2026-03-05
Recruiting
Instituto de Investigación Biomédica de Salamanca
Phase 3
300
Salamanca, Almería, Barakaldo, Girona, Las Palmas de Gran Canaria, Madrid, Murcia, Santander
2026-03-01
Recruiting
Genmab
Phase 2
240
A Coruña, Barcelona, Las Palmas de Gran Canaria, Logroño, Madrid, Málaga, Pamplona, Valencia
2026-01-30
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
170
Logroño, Las Palmas de Gran Canaria, Barcelona, Madrid
2026-01-29
Recruiting
Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Controls Versus Ozone Treatment. (MicrOzoGineTox)
NCT07259681Pelvic Toxicity, Radiation Toxicity, Chemotherapy Toxicity, Gynecological Tumors
Bernardino Clavo, MD, PhD
Observational
38
Las Palmas de Gran Canaria, San Cristóbal de La Laguna
2026-01-15
Recruiting
Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029.
NCT07325851Chemotherapy-Induced Peripheral Neuropathy, Radiation Toxicity, Chronic Pain, Delayed Wound Healing
Bernardino Clavo, MD, PhD
Observational
120
Las Palmas de Gran Canaria
2026-01-14
Recruiting
Sergio Mies Padilla
Not applicable
256
Las Palmas de Gran Canaria
2026-01-12
Recruiting
AbbVie
Phase 2/3
680
Santiago de Compostela, Badalona, Santander, Las Palmas de Gran Canaria, Pamplona, Barcelona, León, Madrid
2026-01-08
Recruiting
Eli Lilly and Company
Phase 3
800
Badajoz, Barcelona, Cáceres, Donostia / San Sebastian, Granada, Hospitalet, Jaén, Las Palmas de Gran Canaria
2025-12-22
Active, closed
Taiho Oncology, Inc.
Phase 3
360
Palma de Mallorca, Badalona, Barcelona, Sabadell, Granada, Las Palmas de Gran Canaria, Lugo, Madrid
2025-12-22
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Badalona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Santander, Oviedo, Alicante, Barcelona, Burgos
2025-11-25
Recruiting
Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice
NCT07252765Type 2 Diabetes Mellitus (T2DM), Malnutrition, Malnourishment, Drug-Induced Diabetes
Outcomes'10
Observational
334
Santander, Huelva, Las Palmas de Gran Canaria, Madrid, Málaga, Oviedo, Seville, Valencia
2025-11-20
Recruiting
Postoperative Analgesia in Thoracic Surgery
NCT07694141Postoperative Pain Management
Hospital Universitario de Gran Canaria Doctor Negrín
Observational
160
Las Palmas de Gran Canaria
2025-11-15
Recruiting
AbbVie
Phase 2
400
Santander, Donostia / San Sebastian, Las Palmas de Gran Canaria, Majadahonda, Seville, A Coruña, Barcelona, Girona
2025-11-13
Active, closed
Hoffmann-La Roche
Phase 2
193
Las Palmas de Gran Canaria, EL Palmar (EL Palmar), Albacete, Alicante, Barcelona, Madrid, Seville
2025-11-13
Recruiting
Boehringer Ingelheim
Phase 3
670
A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga, Palma de Mallorca
2025-11-07
Recruiting
Sanofi
Phase 2
208
Santiago de Compostela, Las Palmas de Gran Canaria, Manises, Cadiz, Granada, Madrid
2025-11-06
Active, closed
Bluefin Biomedicine, Inc.
Phase 2/3
210
Granada, Granollers, Las Palmas de Gran Canaria, Madrid, Pontevedra, Valencia
2025-11-03
Recruiting
Takeda
Phase 2
200
Las Palmas de Gran Canaria, Córdoba, Madrid, Valencia
2025-11-03
Recruiting
Hoffmann-La Roche
Phase 3
600
Palma de Mallorca, Santander, Las Palmas de Gran Canaria, Pamplona, Barcelona, Madrid, Málaga, Seville
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
A Coruña, Barcelona, Burgos, Castellion, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga
2025-10-24
Recruiting
Novo Nordisk A/S
Phase 3
1,280
A Coruña, Badalona, Barcelona, Bilbao, Córdoba, Donostia / San Sebastian, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria
2025-10-02
Not yet open
Post-ICU Syndrome Over Time in Patients With Respiratory Failure
NCT06857513Post-Intensive Care Syndrome, Quality of Life
Hospital Universitario de Gran Canaria Doctor Negrín
Observational
90
Las Palmas de Gran Canaria
2025-10-01
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Badalona, Barcelona, Las Palmas de Gran Canaria, Alcorcón, Málaga, Salamanca, Seville, Madrid
2025-09-22
Recruiting
A Study to Evaluate the Safety and Performance of a Vestibular Implant in Adults to Provide Balance Restoration
NCT06805175Vestibulopathy, Moderate to Severe Hearing Loss, Normal Hearing, Balance Deficits
Cochlear
Not applicable
18
Las Palmas de Gran Canaria, Pamplona
2025-09-18
Recruiting
BeOne Medicines
Phase 3
500
Badalona, Burgos, Las Palmas de Gran Canaria, Madrid, Majadahonda, Palma de Mallorca, Seville
2025-09-04
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Badalona, Barcelona, Beiro, Córdoba, Galdakao, Huelva, Jaén, Las Palmas de Gran Canaria
2025-07-22
Recruiting
Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer
NCT07100288Ovarian Cancer, Ovarian Cancer (OvCa), Ovarian Adenocarcinoma
Complejo Hospitalario Universitario Insular Materno Infantil
Observational
200
Las Palmas de Gran Canaria
2025-07-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Badalona, Santander, Las Palmas de Gran Canaria, Oviedo, Barcelona, Madrid, Seville, Valencia
2025-07-16
Active, closed
Sanofi
Phase 2
105
Las Palmas de Gran Canaria, Madrid
2025-07-07
Recruiting
Novo Nordisk A/S
Phase 2
200
Granada, Girona, El Palmar, Barcelona, Denia, Las Palmas de Gran Canaria, Madrid, Majadahonda
2025-06-30
Recruiting
Novo Nordisk A/S
Phase 2
200
Granada, El Palmar, Barcelona, Las Palmas de Gran Canaria, Madrid, Valencia
2025-06-27
Recruiting
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
NCT06409936CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia
DrugsAsciminib·Nilotinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2
160
Barcelona, Bilbao, Girona, Granada, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca
2025-06-26
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Córdoba, Málaga, Las Palmas de Gran Canaria, Badalona, Barcelona, L'Hospitalet de Llobregat, Lleida, A Coruña
2025-06-25
Active, closed
AbbVie
Phase 3
573
Santiago de Compostela, Granollers, Manresa, Las Palmas de Gran Canaria, Alcorcón, Majadahonda, Gijón, Seville
2025-06-17
Active, closed
Incyte Corporation
Phase 3
573
Barcelona, Esplugues de Llobregat, Granada, Granollers, Las Palmas de Gran Canaria, Madrid, Manises, Santiago de Compostela
2025-06-12
Active, closed
Incyte Corporation
Phase 3
9
Badalona, Barcelona, El Palmar, Esplugues de Llobregat, Granada, Las Palmas de Gran Canaria, Madrid, Málaga
2025-06-04
Recruiting
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
NCT05815927Oligometastatic Squamous Cell Carcinoma of the Head and Neck
DrugPembrolizumab
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
200
Badalona, Barakaldo, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga
2025-05-23
Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab
AstraZeneca
Phase 2
150
Barcelona, Girona, Las Palmas de Gran Canaria, Lugo, Madrid, Santiago de Compostela
2025-05-15
Recruiting
Apogee Therapeutics, Inc.
Phase 2
350
Santiago de Compostela, Las Palmas de Gran Canaria, Madrid
2025-05-14
Recruiting
Ultrasound-Innovation Medtech, S.L.
Not applicable
457
A Coruña, Barcelona, Bilbao, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Málaga
2025-05-10
By invitation
Novo Nordisk A/S
Observational
1,250
Barcelona, Cartagena, Castilleja de la Cuesta, El Palmar (Murcia), Ferrol, Getafe (Madrid), La Cuesta (Santa Cruz de Tenerife), Las Palmas de Gran Canaria
2025-05-01
Recruiting
Gilead Sciences
Phase 3
695
A Coruña, Barcelona, Girona, Jaén, Las Palmas de Gran Canaria, Madrid, Málaga, Seville
2025-04-04
Recruiting
Eli Lilly and Company
Phase 3
700
Badajoz, Barcelona, Hospitalet, Jerez de la Frontera, Las Palmas de Gran Canaria, Madrid, Málaga, Palma
2025-03-27
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
DrugIntismeran autogene
Merck Sharp & Dohme LLC
Phase 2
308
Sabadell, Las Palmas de Gran Canaria, Madrid, Seville
2025-03-11
Recruiting
Incyte Corporation
Phase 3
600
Alcorcón, Alicante, Badalona, Barcelona, Córdoba, Granada, Las Palmas de Gran Canaria, Madrid
2025-02-28
Active, closed
Amgen
Phase 2
252
Las Palmas de Gran Canaria, Barcelona, A Coruña, Madrid
2025-02-26
Recruiting
Evaluation of the WARIFA App and Its Impact on Healthy Lifestyle
NCT06918444Lifestyle Intervention, Non Communicable Chronic Diseases, Type 1 Diabetes (T1D)
Instituto Universitario de Investigaciones Biomédicas y Sanitarias (iUIBS) de la Universidad de Las
Not applicable
104
Las Palmas de Gran Canaria
2025-02-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Seville, L'Hospitalet de Llobregat, Barakaldo, Las Palmas de Gran Canaria, Majadahonda, Gijón, Alicante, Barcelona
2025-01-27
Recruiting
Influence of Preoperative Fear on Pain and Postoperative Outcomes
NCT06785389Fear, Pain Management, Anxiety, Complications of Surgical Procedures or Medical Care
Hospital Universitario de Gran Canaria Doctor Negrín
Observational
138
Las Palmas de Gran Canaria
2025-01-22
Recruiting
Incyte Corporation
Phase 3
240
Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca, Seville
2025-01-21
Recruiting
BioNTech SE
Phase 2/3
1,580
A Coruña, Badajoz, Badalona, Barcelona, Castellon, Las Palmas de Gran Canaria, León, Lleida
2025-01-07
Recruiting
Fundación para la Investigación Biosanitaria del Principado de Asturias
Not applicable
250
Alicante, Barcelona, L'Hospitalet de Llobregat, Santander, Córdoba, Las Palmas de Gran Canaria, Madrid, Málaga
2024-12-24
Recruiting
OSE Immunotherapeutics
Phase 3
363
Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barakaldo, A Coruña, Las Palmas de Gran Canaria, Majadahonda, Marbella
2024-12-03
Recruiting
AstraZeneca
Phase 3
1,160
Barcelona, Castellon, Las Palmas de Gran Canaria, Madrid, Majadahonda, Seville
2024-11-27
Active, closed
Genmab
Phase 3
191
L'Hospitalet de Llobregat, Córdoba, Santiago de Compostela, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Marbella, Pamplona, Alicante
2024-11-25
Recruiting
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2
45
A Coruña, Palma de Mallorca, Santander, Salamanca, Barcelona, L'Hospitalet de Llobregat, San Sebastián, Las Palmas de Gran Canaria
2024-11-20
Recruiting
AstraZeneca
Phase 3
1,160
Barcelona, Las Palmas de Gran Canaria, Lleida, Madrid, Majadahonda, Seville
2024-11-18
Active, closed
Regeneron Pharmaceuticals
Phase 2
120
Badalona, Santander, Las Palmas de Gran Canaria, Pamplona, Madrid, Seville, Valencia, Zaragoza
2024-11-18
Recruiting
Abivax S.A.
Phase 2
212
Barcelona, Córdoba, Fuenlabrada, Huelva, Las Palmas de Gran Canaria, Santiago de Compostela, Seville, Valencia
2024-10-30
Recruiting
Ultrasound to Check the Position of the Nasogastric Tube
NCT06635915Nasogastric Tube Placement
Hospital Universitario de Gran Canaria Doctor Negrín
Not applicable
114
Palmas de GRAN Canaria, LAS, Las Palmas de Gran Canaria
2024-10-15
Recruiting
Fundación EPIC
Observational
234
A Coruña, Aravaca, Barcelona, Córdoba, Fuencarral-El Pardo, Gijón, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria
2024-10-10
Recruiting
PETHEMA Foundation
Phase 2
106
Alicante, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Marbella, Málaga, Oviedo
2024-09-02
Active, closed
Sanofi
Phase 2
229
Barcelona, Chiclana de la Frontera, Las Palmas de Gran Canaria, Seville, Madrid, Málaga
2024-08-29
Recruiting
AstraZeneca
Phase 3
1,018
Barcelona, El Palmar, Girona, Las Palmas de Gran Canaria, Madrid, Oviedo, Pamplona, Santander
2024-08-07
Active, closed
AstraZeneca
Phase 3
339
Barcelona, Castellon, Granada, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca
2024-06-29
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Huelva, Bilbao, Las Palmas de Gran Canaria, Salamanca, Barcelona, Cataluna, Majadahonda, Islas Baleares
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Santiago de Compostela, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Seville
2024-06-10
Active, closed
The Lymphoma Academic Research Organisation
Phase 3
790
Albacete, Barcelona, Las Palmas de Gran Canaria, Lleida, Madrid, Marbella, Oviedo, Salamanca
2024-06-07
Recruiting
X4 Pharmaceuticals
Phase 3
176
Barcelona, Cáceres, Córdoba, Las Palmas de Gran Canaria, Madrid, Santander, Seville, Valencia
2024-06-06
Recruiting
Immunocore Ltd
Phase 3
680
Santander, El Palmar, A Coruña, Barcelona, Córdoba, Granada, Las Palmas de Gran Canaria, Madrid
2024-06-05
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Badalona, Barcelona, Cáceres, Las Palmas de Gran Canaria, Madrid, Málaga, Salamanca, Valencia
2024-06-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Las Palmas de Gran Canaria, Leganés, Madrid, Málaga, Barcelona, Seville
2024-05-24
Recruiting
Daiichi Sankyo
Phase 3
540
Barcelona, Córdoba, Jaén, Jerez de la Frontera, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga
2024-05-21
Recruiting
GELLC (Grupo Español de Leucemia Linfocítica Crónica)
Phase 2
34
Barcelona, L'Hospitalet de Llobregat, Santander, Las Palmas de Gran Canaria, Madrid, Murcia, Marbella, Oviedo
2024-05-15
Active, closed
Sanofi
Phase 3
1,541
Esplugues de Llobregat, Bilbao, Las Palmas de Gran Canaria, Pamplona, Vigo, Seville, Burjassot - Valencia, Alicante
2024-05-08
Recruiting
Residual Neuromuscular Block in the Post-Anesthetic Unit and Postoperative Complications
NCT06386354Postoperative Neuromuscular Block, Postoperative Complications
Hospital Universitario de Gran Canaria Doctor Negrín
Observational
296
Las Palmas de Gran Canaria
2024-05-01
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
470
Santiago de Compostela, Badalona, Las Palmas de Gran Canaria, Alicante, Barcelona, Madrid, Zaragoza
2024-04-29
Recruiting
Karyopharm Therapeutics Inc
Phase 2
58
Badalona, El Palmar, Oviedo, Cáceres, Girona, Las Palmas de Gran Canaria, Salamanca, Valencia
2024-04-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
L'Hospitalet de Llobregat, Santiago de Compostela, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Barcelona, Madrid
2024-04-03
Recruiting
Hospital Universitario de Gran Canaria Doctor Negrín
Observational
138
Las Palmas de Gran Canaria
2024-03-01
Recruiting
"Multicenter Registry for Chest Wall Reconstruction Using Custom Dynamic Prostheses (PRODIPET)"
NCT07018960Chest Wall Tumors, Post-traumatic Syndrome, Malignant Bone Tumor of Chest Wall
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Not applicable
60
Cruces, Las Palmas de Gran Canaria, Barcelona, Madrid, Alzira
2024-03-01
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Málaga, Seville, Zaragoza, Las Palmas de Gran Canaria, Badalona, Barcelona, Santiago de Compostela, Majadahonda
2024-02-20
Active, closed
AbbVie
Observational
1,200
Sant Joan Despí, Jerez de la Frontera, Córdoba, Las Palmas de Gran Canaria, Leganés, Oviedo, Galdakao, Barcelona
2024-02-19
Active, closed
Incyte Corporation
Phase 3
617
Alicante, Badalona, Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Manises, Pontevedra
2024-01-30
Active, closed
BicycleTx Limited
Phase 2
375
Barcelona, Las Palmas de Gran Canaria, Madrid, Pamplona, San Sebastián, Santander, Santiago de Compostela, Valencia
2024-01-24
Active, closed
Pfizer
Phase 3
394
Córdoba, Barcelona, Las Palmas de Gran Canaria, Madrid
2024-01-19
Recruiting
Daiichi Sankyo
Phase 3
250
Barcelona, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Majadahonda, Murcia, Pamplona
2023-12-30
Active, closed
Sanofi
Phase 3
943
Murcia, Barcelona, Barakaldo, L'Hospitalet de Llobregat, Donostia / San Sebastian, Girona, Las Palmas de Gran Canaria, Lleida
2023-12-27
Recruiting
Eli Lilly and Company
Phase 3
1,264
A Coruña, Badajoz, Barakaldo, Barcelona, Hospitalet, Jerez de la Frontera, Las Palmas de Gran Canaria, León
2023-12-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Sabadell, Barcelona, Girona, A Coruña, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Burgos, Málaga
2023-12-18
Active, closed
Sanofi
Phase 3
1,655
Murcia, Barcelona, Barakaldo, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Pontevedra, Seville, Córdoba
2023-12-13
Active, closed
PETHEMA Foundation
Phase 2
50
Santiago de Compostela, Palma de Mallorca, Badalona, Santander, Jerez de la Frontera, Las Palmas de Gran Canaria, El Palmar, Barcelona
2023-11-23
Recruiting
Amgen
Phase 3
750
Málaga, Seville, Zaragoza, Palma de Mallorca, Las Palmas de Gran Canaria, Santander, Valladolid, Barcelona
2023-11-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Barcelona, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Madrid, Málaga
2023-11-12
Active, closed
BeOne Medicines
Phase 3
652
Burgos, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Santa Cruz de Tenerife
2023-11-11
Active, closed
AbbVie
Observational
146
Vitoria-Gasteiz, Manresa, Terrassa, Jerez de la Frontera, Laredo, Santander, Las Palmas de Gran Canaria, León
2023-11-06
Active, closed
Summit Therapeutics
Phase 3
1,600
Badajoz, Badalona, Barcelona, Girona, Jaén, Las Palmas de Gran Canaria, Lugo, Madrid
2023-10-26
Active, closed
iVascular S.L.U.
Phase 3
2,312
A Coruña, Almería, Barcelona, Cáceres, Huelva, Jerez de la Frontera, Las Palmas de Gran Canaria, León
2023-10-13
Recruiting
AstraZeneca
Observational
52,121
A Coruña, Barcelona, Bilbao, El Palmar, Huelva, Las Palmas de Gran Canaria, Madrid, Majadahonda
2023-08-21
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
36
Pamplona, Barcelona, Las Palmas de Gran Canaria, Madrid
2023-06-27
Active, closed
Swedish Orphan Biovitrum
Observational
165
Badalona, Barakaldo, Barcelona, Bilbao, Donostia / San Sebastian, El Palmar, Huelva, Las Palmas de Gran Canaria
2023-06-26
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Barcelona, Cáceres, Las Palmas de Gran Canaria, Murcia, Oviedo, Valencia, Badalona, Madrid
2023-06-22
Active, closed
Alfasigma S.p.A.
Observational
509
Barcelona, Badalona, Las Palmas de Gran Canaria, Palma de Mallorca, Santiago de Compostela
2023-06-12
By invitation
Hospital Universitario de Gran Canaria Doctor Negrín
Observational
400
Las Palmas de Gran Canaria
2023-05-13
Active, closed
Assessment of PaO2/FiO2 Ratio Pre and POst INTubation
NCT05853068Acute Hypoxemic Respiratory Failure
Hospital Universitario de Gran Canaria Doctor Negrín
Observational
400
Las Palmas de Gran Canaria
2023-04-29
Recruiting
University of Las Palmas de Gran Canaria
Not applicable
30
Las Palmas de Gran Canaria
2023-04-24
Active, closed
Bristol-Myers Squibb
Phase 3
579
A Coruña, Barcelona, Donostia / San Sebastian, Jaén, Madrid, Valencia, Badalona, Las Palmas de Gran Canaria
2023-03-06
Active, closed
Novo Nordisk A/S
Phase 3
7,101
Fuenlabrada, Alzira, Antequera, Barcelona, Castilleja de la Cuesta, Córdoba, Las Palmas de Gran Canaria, Madrid
2023-03-01
Active, closed
Gilead Sciences
Phase 2
400
Barcelona, Las Palmas de Gran Canaria, Lugo, Málaga, Seville, Valencia
2023-02-21
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Córdoba, Santiago de Compostela, Las Palmas de Gran Canaria, Fuenlabrada, Barcelona, Girona, Huelva, Madrid
2023-01-16
Active, closed
AstraZeneca
Phase 3
1,350
Las Palmas de Gran Canaria, Lugo, Madrid, Santander, Seville, Valencia, Zaragoza
2022-12-29
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
6,000
Palma de Mallorca, Granollers, L'Hospitalet de Llobregat, Ferrol, Santiago de Compostela, Logroño, Las Palmas de Gran Canaria, Marbella
2022-11-21
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Not applicable
600
Badajoz, Las Palmas de Gran Canaria, Majadahonda
2022-10-27
Active, closed
Gilead Sciences
Phase 3
1,021
Barcelona, Córdoba, Girona, Jaén, Las Palmas de Gran Canaria, Madrid, Majadahonda, Reus
2022-10-12
Recruiting
EMD Serono Research & Development Institute, Inc.
Observational
700
Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Seville, Valencia
2022-10-04
Recruiting
Ellipses Pharma
Phase 1/2
265
A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga
2022-09-30
Active, closed
Sanofi
Phase 2/3
1,856
Badalona, Bilbao, Las Palmas de Gran Canaria, Pamplona, Pontevedra, Vigo, Seville, Burjassot
2022-08-22
Active, closed
AbbVie
Observational
785
L'Hospitalet de Llobregat, Sabadell, Las Palmas de Gran Canaria, Gijón, San Cristóbal de La Laguna, Seville, Galdakao, Almería
2022-08-15
Active, closed
Janssen Research & Development, LLC
Phase 3
418
A Coruña, Alicante, Barcelona, Córdoba, Las Palmas de Gran Canaria, Lugo, Madrid, Majadahonda
2022-08-05
Active, closed
Daiichi Sankyo
Phase 3
586
A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Santander, Seville
2022-07-08
Recruiting
Orphalan
Observational
500
Las Palmas de Gran Canaria, Barcelona, Seville, Valencia
2022-06-29
Recruiting
Priothera SAS
Phase 3
366
Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Salamanca, Valencia
2022-06-16
Recruiting
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
DrugELVN-001
Enliven Therapeutics
Phase 1
250
Barcelona, Las Palmas de Gran Canaria, Madrid, Toledo, Valencia
2022-05-22
Recruiting
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
NCT04493632Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
OncoSil Medical Limited
Observational
500
Las Palmas de Gran Canaria, Madrid, Pamplona, Valladolid
2022-04-12
Recruiting
University of Las Palmas de Gran Canaria
Not applicable
42
Las Palmas de Gran Canaria
2022-03-28
Recruiting
AbbVie
Phase 3
768
Las Palmas de Gran Canaria, Alcorcón, Fuenlabrada, Ávila, Barcelona, Jaén, Madrid, Valencia
2022-03-25
Recruiting
University of Las Palmas de Gran Canaria
Observational
600
Las Palmas de Gran Canaria
2022-03-22
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Santiago de Compostela, L'Hospitalet de Llobregat, Córdoba, Las Palmas de Gran Canaria, Majadahonda, Barcelona, Madrid
2022-01-13
Recruiting
Pathological Response After Neoadjuvant Treatment on NSCLC
NCT05167487Stage IIIA Non-small Cell Lung Cancer
DrugsParaplatin·Cisplatin·Carboplatin
Fundación GECP
Observational
150
A Coruña, Alicante, Badalona, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda
2021-12-13
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Barakaldo, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Pamplona
2021-12-10
Active, closed
Fundación GECP
Phase 2
71
Badalona, Barcelona, L'Hospitalet de Llobregat, Castellon, Las Palmas de Gran Canaria, Jaén, A Coruña, León
2021-11-18
Active, closed
Janssen Research & Development, LLC
Phase 3
776
A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Pamplona, Seville
2021-11-17
Active, closed
Cullinan Therapeutics Inc.
Phase 1
440
Las Palmas de Gran Canaria, Barcelona, Madrid, Pamplona, Sabadell
2021-10-29
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Barcelona, Gijón, Las Palmas de Gran Canaria, Madrid, Palma, Pamplona, Pozuelo de Alarcón, Salamanca
2021-10-14
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
Guardant Health, Inc.
Observational
2,285
A Coruña, Barcelona, Girona, Las Palmas de Gran Canaria, Madrid, Málaga, Sabadell, Santiago de Compostela
2021-09-07
Active, closed
AstraZeneca
Phase 3
712
Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Pamplona, Seville
2021-08-05
Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Pierre Fabre Medicament
Phase 1
400
Barcelona, Madrid, Málaga, Seville, Valencia, Las Palmas de Gran Canaria
2021-08-04
Recruiting
PEEP in Patients With Acute Respiratory Failure
NCT04912960Acute Respiratory Failure With Hypoxia
Jesus Villar
Observational
15
Las Palmas de Gran Canaria, Barcelona, Madrid
2021-06-10
Recruiting
University of Las Palmas de Gran Canaria
Not applicable
40
Las Palmas de Gran Canaria
2021-05-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Badalona, Manresa, Girona, Santiago de Compostela, Las Palmas de Gran Canaria, Oviedo, Valencia, Barcelona
2021-04-21
Active, closed
Geron Corporation
Phase 3
327
Alicante, Badalona, Las Palmas de Gran Canaria, Cáceres, Granada, Madrid, Málaga, Zaragoza
2021-04-12
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Oviedo, Badalona, Barcelona, Cáceres, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca
2021-04-09
Active, closed
PETHEMA Foundation
Phase 2
50
Palma de Mallorca, Santander, Salamanca, Santiago de Compostela, Madrid, Gijón, Valencia, Las Palmas de Gran Canaria
2021-04-07
Active, closed
Karyopharm Therapeutics Inc
Phase 3
353
Cáceres, Oviedo, Zaragoza, Badalona, Barcelona, Girona, Las Palmas de Gran Canaria, Lugo
2021-03-11
Recruiting
sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.
NCT04766866Preeclampsia, Intrauterine Growth Restriction, Maternal Hypertension, Neonatal Outcome
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Not applicable
9,132
Badalona, Las Palmas de Gran Canaria, El Palmar, Barcelona, Madrid, Palma de Mallorca, Valencia, Zaragoza
2021-03-02
Active, closed
Celgene
Phase 3
313
Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Palma de Mallorca, Salamanca, Santiago de Compostela, Seville
2021-02-25
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
DrugRuxolitinib
Incyte Corporation
Phase 1
140
Badalona, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca
2021-02-23
Active, closed
Galderma R&D
Phase 3
500
Barcelona, Las Palmas de Gran Canaria
2021-01-11
Recruiting
FS222 First in Human Study in Patients With Advanced Malignancies
NCT04740424Advanced Cancer, Metastatic Cancer
invoX Pharma Limited
Phase 1
260
Pamplona, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Seville, Valencia
2020-12-14
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Pamplona, A Coruña, Badalona, Barcelona, Bilbao, Burgos, Jerez de la Frontera, Las Palmas de Gran Canaria
2020-12-02
Recruiting
Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)
NCT04299893Chemotherapy-induced Peripheral Neuropathy, Pain, Neuropathic, Pain Syndrome
DrugOzone
Bernardino Clavo, MD, PhD
Phase 2/3
42
Las Palmas de Gran Canaria
2020-11-30
Active, closed
Hoffmann-La Roche
Phase 3
210
Bilbao, Badalona, Las Palmas de Gran Canaria, Barcelona, Cáceres, Madrid, Salamanca
2020-10-08
Active, closed
AbbVie
Phase 3
330
A Coruña, Santiago de Compostela, Badalona, Las Palmas de Gran Canaria, Oviedo, Barcelona, Granada, Madrid
2020-08-31
Recruiting
Meril Life Sciences Pvt. Ltd.
Observational
200
Las Palmas de Gran Canaria, Valladolid
2020-08-07
Active, closed
AstraZeneca
Phase 3
1,012
Badalona (Barcelona), Barcelona, Las Palmas de Gran Canaria, Madrid, Oviedo, Santander, Seville
2020-07-13
Active, closed
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
NCT04223596Lung Cancer, NSCLC, NSCLC Stage IIIB, NSCLC Stage IV
DrugBrigatinib
Fundación GECP
Phase 2
33
A Coruña, Alicante, Málaga, Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barcelona, Las Palmas de Gran Canaria
2020-05-04
Active, closed
Eli Lilly and Company
Phase 3
261
Palma de Mallorca, Badalona, Santiago de Compostela, Las Palmas de Gran Canaria, Majadahonda, Pamplona, Alicante, Barcelona
2020-02-17
Active, closed
Daiichi Sankyo
Phase 1
115
A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Seville, Zaragoza
2020-02-10
Active, closed
Sun Pharmaceutical Industries Limited
Phase 2/3
135
Barcelona, Las Palmas de Gran Canaria
2020-01-15
Recruiting
Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer
NCT06747481Pancreatic Cancer, Adult, Perineural Invasion, Neutrophil-to-Lymphocyte Ratio, CA 19.9
University of Las Palmas de Gran Canaria
Observational
323
Las Palmas de Gran Canaria
2020-01-01
Active, closed
Galderma R&D
Phase 3
1,700
Alicante, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Pamplona
2019-12-30
Active, closed
Registry Study of Pregnancy and Breast Cancer
NCT04603820Breast Cancer and Pregnancy
Spanish Breast Cancer Research Group
Observational
866
Palma de Mallorca, Badalona, Terrassa, Bilbao, Santa Cruz de Tenerife, A Coruña, Las Palmas de Gran Canaria, Leganés
2019-11-18
Active, closed
PETHEMA Foundation
Phase 3
302
Santiago de Compostela, Vitoria-Gasteiz, Badalona, Hospitalet Del Llobregat, San Sebastián, Jaén, Las Palmas de Gran Canaria, Pozuelo de Alarcón
2019-09-24
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Pamplona, Santiago de Compostela
2019-09-17
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Alcalá de Henares, Badalona, Barcelona, Burgos, Córdoba, Las Palmas de Gran Canaria, Madrid, Majadahonda
2019-08-15
Active, closed
Sanofi
Observational
955
Bilbao, Las Palmas de Gran Canaria, Majadahonda, Oviedo, Barakaldo, Barcelona, Madrid, Santiago de Compostela
2019-06-11
Active, closed
NADIM II: Neo-Adjuvant Immunotherapy
NCT03838159Non Small Cell Lung Cancer
DrugsParaplatin·Taxol·Opdivo·Nivolumab
Fundación GECP
Phase 2
90
Alicante, Badalona, Barcelona, L'Hospitalet de Llobregat, Córdoba, Girona, Las Palmas de Gran Canaria, A Coruña
2019-05-15
Active, closed
Kartos Therapeutics, Inc.
Phase 2
20
Las Palmas de Gran Canaria, Málaga, Salamanca
2019-01-15
Active, closed
AstraZeneca
Phase 3
1,063
Badalona, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Santander, Seville
2018-11-16
Active, closed
AbbVie
Phase 2
270
Santiago de Compostela, Badalona, Las Palmas de Gran Canaria, Alcorcón, Ávila, Barcelona, Madrid, Málaga
2018-10-10
Recruiting
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
NCT03567889Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
DrugDaromun
Philogen S.p.A.
Phase 3
186
Badalona, Barcelona, Las Palmas de Gran Canaria, Donostia / San Sebastian, Madrid, Málaga, Murcia, Seville
2018-09-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Badalona, L'Hospitalet de Llobregat, Girona, Las Palmas de Gran Canaria, Barcelona, Madrid, Seville
2018-04-24
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Badajoz, Badalona, Barcelona, Cáceres, Córdoba, Granada, Jaén, Las Palmas de Gran Canaria
2018-03-23
Active, closed
AbbVie
Phase 3
747
Palma de Mallorca, Santander, Las Palmas de Gran Canaria, Pamplona, A Coruña, Barcelona, Girona, Huelva
2018-03-21
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
885
Alcorcón, Barcelona, Bilbao, Cartagena, Córdoba, Las Palmas de Gran Canaria, Pamplona, Sabadell
2017-09-25
Active, closed
Hoffmann-La Roche
Phase 3
382
Palma de Mallorca, Córdoba, A Coruña, Las Palmas de Gran Canaria, Pamplona, Barcelona, Cáceres, Jaén
2017-09-20
Recruiting
Registry for Patients With X-Linked Hypophosphatemia
NCT03193476X-Linked Hypophosphatemia
Kyowa Kirin Pharmaceutical Development Ltd
Observational
1,489
Barakaldo, Barcelona, Cartagena, El Palmar, Esplugues de Llobregat, Las Palmas de Gran Canaria, Madrid, Oviedo
2017-09-12
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Santiago de Compostela, Palma de Mallorca, Badalona, Las Palmas de Gran Canaria, Barcelona, Madrid, Seville, Valencia
2017-06-26
Active, closed
Pfizer
Phase 3
296
L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Majadahonda, Pamplona, A Coruña, Barcelona, Girona, Madrid
2017-04-27
Active, closed
AbbVie
Phase 3
950
A Coruña, Santiago de Compostela, Santander, Las Palmas de Gran Canaria, Barcelona, Córdoba, Madrid, Salamanca
2017-01-31
Recruiting
Spanish Breast Cancer Research Group
Observational
1,867
Elche, Manresa, Terrassa, San Sebastián, Las Palmas de Gran Canaria, Alcorcón, Fuenlabrada, Leganés
2016-08
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Barakaldo, Barcelona, Castellon, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga, Reus
2015-11-19
Active, closed
AstraZeneca
Phase 3
682
A Coruña, Barcelona, Donostia / San Sebastian, Elche, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga
2015-10-21
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
A Coruña, Badalona, Barcelona, Castellon, Girona, Guadalajara, Jerez de la Frontera, Las Palmas de Gran Canaria
2013-10-14
Rows per page Showing 1–203 of 203
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/las-palmas-de-gran-canaria

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 203 of those studies with a site in Las Palmas de Gran Canaria.

How many clinical trials are recruiting in Las Palmas de Gran Canaria?

111 of the 203 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 5 have not yet opened recruitment, 85 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Las Palmas de Gran Canaria), 203 studies
PhaseStudiesRecruitingShare
Phase 31014849.8%
Observational362317.7%
Phase 2321615.8%
Not applicable14126.9%
Phase 2/3843.9%
Phase 1743.4%
Phase 1/2542.5%

Most active sponsors

Lead sponsors with the most studies (Las Palmas de Gran Canaria)
Lead sponsorStudiesRecruiting
AstraZeneca159
Merck Sharp & Dohme LLC1310
AbbVie123
Incyte Corporation106
Hospital Universitario de Gran Canaria Doctor Negrín85
Sanofi81
Daiichi Sankyo53
Eli Lilly and Company54
Hoffmann-La Roche51
Janssen Research & Development, LLC50
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.